• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氧氟沙星,一种用于治疗泌尿生殖系统感染和肠道感染的新型喹诺酮类药物。

Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections.

作者信息

Tanphaichitra D, Sahaphong S, Srimuang S

出版信息

Infection. 1986;14 Suppl 4:S321-3. doi: 10.1007/BF01661308.

DOI:10.1007/BF01661308
PMID:3102387
Abstract

During 1984 to 1986, 121 patients with gonorrhoea were treated with ofloxacin. This report is to summarize the results of our trial in patients treated with three different dose regimens of ofloxacin: A) a single 800 mg dose of ofloxacin (32 patients); B) a single 400 mg dose of ofloxacin (55 patients) or C) a twice a day dose of 600 mg ofloxacin (34 patients). In addition, 19 patients with urinary tract infection and eight patients with enteric fever were treated with 400 mg ofloxacin twice a day for seven to ten days. Out of 121 patients with gonococcal urethritis, only 107 patients were evaluable. Cure was obtained in 96.5%; 93.2% and 94.5% of the patients in groups A, B and C respectively. 16 out of 17 patients with urinary tract infection achieved clinical cure or improvement. The 16 patients were bacteriologically accessible; pathogens were eradicated in all of them. Ofloxacin was also effective in the treatment of enteric fever, in which eradication was achieved in all seven patients. 28% of Neisseria gonorrhoea and 29% of Salmonella spp. isolated in our community were beta-lactamase-positive.

摘要

1984年至1986年期间,121例淋病患者接受了氧氟沙星治疗。本报告旨在总结我们对使用三种不同剂量方案的氧氟沙星治疗患者的试验结果:A)单次服用800毫克氧氟沙星(32例患者);B)单次服用400毫克氧氟沙星(55例患者)或C)每天两次服用600毫克氧氟沙星(34例患者)。此外,19例尿路感染患者和8例肠热症患者接受了每天两次400毫克氧氟沙星治疗,疗程为7至10天。在121例淋菌性尿道炎患者中,只有107例患者可进行评估。A、B、C组分别有96.5%、93.2%和94.5%的患者治愈。17例尿路感染患者中有16例实现了临床治愈或病情改善。这16例患者可进行细菌学检测;所有患者的病原体均被根除。氧氟沙星对肠热症也有效,7例患者全部实现了病原体根除。在我们社区分离出的淋病奈瑟菌中有28%和沙门氏菌属中有29%是β-内酰胺酶阳性。

相似文献

1
Ofloxacin, a new quinolone in the treatment of genitourinary and enteric infections.氧氟沙星,一种用于治疗泌尿生殖系统感染和肠道感染的新型喹诺酮类药物。
Infection. 1986;14 Suppl 4:S321-3. doi: 10.1007/BF01661308.
2
Single doses of ofloxacin in uncomplicated gonorrhoea.
Drugs. 1987;34 Suppl 1:107-10. doi: 10.2165/00003495-198700341-00023.
3
Efficacy of ofloxacin in uncomplicated gonorrhoea.
Infection. 1986;14 Suppl 4:S311-3. doi: 10.1007/BF01661304.
4
In vitro and clinical evaluation of ofloxacin in urinary tract infection and enteric fever.
Drugs Exp Clin Res. 1988;14(8):529-31.
5
Ofloxacin, a new quinolone for the treatment of gonorrhea.
Sex Transm Dis. 1988 Jan-Mar;15(1):25-6. doi: 10.1097/00007435-198801000-00005.
6
Ofloxacin: clinical evaluation in urinary and respiratory infections.
Infection. 1986;14 Suppl 4:S297-9. doi: 10.1007/BF01661298.
7
Single dose ofloxacin in treatment of uncomplicated gonorrhoea.
Infection. 1986;14 Suppl 4:S314-5. doi: 10.1007/BF01661305.
8
[One-dose treatment of male gonococcal urethritis by ofloxacin].
Pathol Biol (Paris). 1987 May;35(5):642-3.
9
Clinical experience with ofloxacin (DL 8280) in the therapy of various infections: preliminary report.
Infection. 1986;14 Suppl 4:S307-8. doi: 10.1007/BF01661302.
10
Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea. Trovafloxacin Gonorrhea Study Group.曲伐沙星与氧氟沙星单剂量治疗淋病的随机试验。曲伐沙星淋病研究组。
Am J Med. 1998 Jan;104(1):28-32. doi: 10.1016/s0002-9343(97)00277-5.

引用本文的文献

1
Human Immune Responses and the Natural History of Infection.人类免疫反应与感染的自然史。
Front Immunol. 2019 Feb 19;9:3187. doi: 10.3389/fimmu.2018.03187. eCollection 2018.
2
Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever).用于治疗伤寒和副伤寒(肠热病)的氟喹诺酮类药物。
Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD004530. doi: 10.1002/14651858.CD004530.pub4.
3
Quinolones and the gastrointestinal tract.
Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1093-101. doi: 10.1007/BF01975176.

本文引用的文献

1
Cellular immunity in typhoid fever, Legionnaires' disease, amebiasis: role of transfer factor and Levamisole in typhoid fever.伤寒、军团病、阿米巴病中的细胞免疫:转移因子和左旋咪唑在伤寒中的作用
Dev Biol Stand. 1983;53:35-40.
2
The combination of pivmecillinam and pivampicillin in the treatment of enteric fever.匹美西林与匹氨西林联合治疗肠热症
Infection. 1984 Nov-Dec;12(6):381-3. doi: 10.1007/BF01645219.
3
[Clinical studies on DL-8280 in male gonococcal urethritis].
Kansenshogaku Zasshi. 1984 Aug;58(8):784-9. doi: 10.11150/kansenshogakuzasshi1970.58.784.
4
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.氧氟沙星。对其抗菌活性、药理学及治疗用途的重新评估。
Drugs. 1991 Nov;42(5):825-76. doi: 10.2165/00003495-199142050-00008.
4
The combination of pivmecillinam and pivampicillin compared to co-trimoxazole in the treatment of enteric fever.与复方新诺明相比,匹美西林和匹氨西林联合用药治疗伤寒。
Infection. 1982;10(2):81-4. doi: 10.1007/BF01816729.
5
The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever.
J Antimicrob Chemother. 1981 Jul;8(1):23-8. doi: 10.1093/jac/8.1.23.
6
Antibiotic resistance in typhoid fever. Chloramphenicol resistance among clinical isolates of Salmonella typhosa in Los Angeles, 1972--epidemiologic and bacteriologic characteristics.伤寒热中的抗生素耐药性。1972年洛杉矶伤寒沙门氏菌临床分离株中的氯霉素耐药性——流行病学和细菌学特征。
N Engl J Med. 1973 Aug 30;289(9):463-5. doi: 10.1056/NEJM197308302890906.
7
Chloramphenicol resistance in the typhoid bacillus.伤寒杆菌中的氯霉素耐药性。
Br Med J. 1972 Aug 5;3(5822):329-31. doi: 10.1136/bmj.3.5822.329.
8
Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor.越南与R因子相关的耐氯霉素伤寒热
Lancet. 1973 Nov 3;302(7836):983-5. doi: 10.1016/s0140-6736(73)91086-6.
9
Use of temocillin in typhoid fever, hepatobiliary disease and other infections.
Drugs. 1985;29 Suppl 5:201-5. doi: 10.2165/00003495-198500295-00044.
10
Comparative trial of amoxycillin and chloramphenicol in treatment of typhoid fever in adults.
Lancet. 1975 Aug 23;2(7930):333-4. doi: 10.1016/s0140-6736(75)92776-2.